このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Sotatercept in the Treatment of Methamphetamine-Associated Pulmonary Arterial Hypertension (METH-FOCUS)

2026年11月11日 更新者:Jeffrey Robinson、Oregon Health and Science University

Methamphetamine-Associated PAH: Early Therapy With Sotatercept - Feasibility and Outcomes in Clinical Use Study (METH-FOCUS)

The goal of this clinical trial is to find out whether sotatercept, an FDA-approved medication for people with pulmonary arterial hypertension (PAH), can improve health outcomes for people with PAH due to use of methamphetamine. The main question it aims to answer is whether sotatercept added to standard background therapy and addiction medicine services will improve treatment response as measured by:

  • Echocardiographic measurements of pulmonary hypertension
  • Change in 6-minute walk distance (6MWD)
  • Change in categorization of disease (World Health Organization Functional Class, WHO FC)
  • Quality of life improvements

Participants will need to adhere to their standard PAH therapy as well as the prescribed sotatercept, as well as actively engaging with addiction medicine services. They will complete the following activities:

  • Physical exam
  • Labs including drug screening
  • Pulmonary function testing (PFT)
  • Exercise testing (6MWD)
  • Echocardiography
  • Right heart catheterization (RHC)
  • Questionnaires related to their disease

Participants will be in the study for about six months.

調査の概要

状態

まだ募集していません

介入・治療

研究の種類

介入

入学 (推定)

20

段階

  • フェーズ 4

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

  • 名前:Samantha Ruimy, MS
  • 電話番号:503-494-0724
  • メール:ruimy@ohsu.edu

研究連絡先のバックアップ

  • 名前:Allyson Knapper, MD
  • 電話番号:503-494-5531
  • メール:knapper@ohsu.edu

研究場所

    • Hawaii
      • Honolulu、Hawaii、アメリカ、96813
        • The Queen's Medical Center
        • コンタクト:
        • 主任研究者:
          • Gehan Devendra, MD
    • Oregon
      • Portland、Oregon、アメリカ、97239
        • Oregon Health & Science University
        • コンタクト:
        • コンタクト:
          • Samantha Ruimy, MS
          • 電話番号:5034940724
          • メール:ruimy@ohsu.edu
        • 主任研究者:
          • Jeffrey C Robinson, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age ≥ 18 years
  • Documented diagnostic right heart catheterization (RHC) within 12 months of screening documenting a minimum mean PA pressure of 20 mmHg, PVR of ≥ 2 Wood units and pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic pressure (LVEDP) of ≤ 15 mmHg, with the diagnosis of Meth-APAH as defined by patient verbally confirming exposure or having positive toxicology testing for methamphetamine within 5 years of PAH diagnosis
  • Symptomatic PAH classified as WHO FC II or III
  • Diagnosis of PAH within 12 months of screening and on stable doses of a ERA and PDE5i combination of background PAH therapies and diuretics (if any) for at least 90 days prior to screening
  • 6MWD ≥ 150 m completed at screening visit
  • Females of childbearing potential must meet the following criteria: Have 2 negative urine or serum pregnancy tests as verified by the investigator during the Screening Period; Agree to ongoing pregnancy testing (either urine or serum) during the course of the study and until 8 weeks after the last dose of the study drug; If sexually active with a male partner, use highly effective contraception without interruption for at least 28 days prior to starting the investigational product AND agree to use the same highly effective contraception in combination with a barrier method during the study (including dose interruptions), and for 16 weeks (112 days) after discontinuation of study treatment; Refrain from breastfeeding a child or donating blood, eggs, or ovum for the duration of the study and for at least 16 weeks (112 days) after the last dose of study treatment
  • Male participants must meet the following criteria: Agree to use a condom, defined as a male latex condom or nonlatex condom NOT made out of natural (animal) membrane (e.g., polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 16 weeks (112 days) following investigational product discontinuation, even if he has undergone a successful vasectomy; Refrain from donating blood or sperm for the duration of the study and for 16 weeks (112 days) after the last dose of study treatment
  • Ability to adhere to study visit schedule and understand and comply with all protocol requirements
  • Ability to understand and provide documented informed consent

Exclusion Criteria:

  • Diagnosis of PH WHO Groups 2, 3, 4, or 5
  • Diagnosis of the following PAH Group 1 subtypes: human immunodeficiency virus (HIV)-associated PAH, PAH associated with portal hypertension, schistosomiasis- associated PAH, collagen vascular disease- associated PAH, pulmonary veno-occlusive disease, and pulmonary capillary hemangiomatosis
  • Hgb at screening above gender-specific ULN, per local laboratory test
  • Uncontrolled systemic hypertension as evidenced by sitting systolic BP > 180 mmHg or sitting diastolic BP > 110 mmHg during the Screening Visit after a period of rest
  • Baseline systolic BP < 90 mmHg at screening
  • Pregnant or breastfeeding women
  • Any of the following clinical laboratory values at the Screening Visit: eGFR < 30 mL/min/1.73 m2 (as defined by MDRD equation), serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin levels > 3 × ULN, platelet count < 50,000/mm3 (< 50.0 × 109/L)
  • Currently enrolled in or have completed any other investigational product study within 30 days for small-molecule drugs or within 5 half-lives for investigational biologics prior to the date of documented informed consent
  • Known allergic reaction to sotatercept (ACE-011), its excipients, or luspatercept
  • History of pneumonectomy
  • Pulmonary function test values of forced vital capacity < 60% predicted within 1 year prior to the Screening Visit
  • Stopped receiving any PH chronic general supportive therapy (e.g., diuretics, oxygen, anticoagulants, and digoxin) within 60 days prior to the Screening Visit
  • Initiation of an exercise program for cardiopulmonary rehabilitation within 90 days prior to the Screening Visit or planned initiation during the study (participants who are stable in the maintenance phase of a program and who will continue for the duration of the study are eligible)
  • Untreated more than mild obstructive sleep apnea
  • History of known pericardial constriction
  • History of restrictive cardiomyopathy
  • History of atrial septostomy within 180 days prior to the Screening Visit
  • Personal or family history of long QT syndrome or sudden cardiac death
  • Left ventricular ejection fraction < 50% documented by a historical ECHO or cardiac MRI within the last 12 months prior to screening (if there is more than one assessment of LVEF, the value from the most recent measurement should be used in assessing eligibility)
  • Coronary artery disease (myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or cardiac anginal chest pain) within 6 months prior to the Screening Visit
  • Cerebrovascular accident within 3 months prior to the Screening Visit
  • Acutely decompensated left heart failure within 30 days prior to the Screening Visit, as per investigator assessment
  • Significant (≥ 2+ regurgitation) mitral regurgitation or aortic regurgitation valvular disease
  • Received intravenous inotropes (e.g., dobutamine, dopamine, norepinephrine, and vasopressin) within 30 days prior to the Screening Visit
  • Active malignancy with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or prostate cancer that is not currently or expected, during the study, to be treated with radiation therapy, chemotherapy, and/or surgical intervention, or hormonal treatment.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Sotatercept with addiction medicine services

Sotatercept given in coordination with addiction medicine services

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Treatment response in methamphetamine-associated PAH
時間枠:24 weeks

The main hypothesis is that the addition of sotatercept to standard background therapy and addiction medicine services will improve treatment response in meth-APAH, as measured by the echocardiographic parameter TAPSE divided by RVSP (mm/mmHg).

24 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Jeffrey C Robinson, MD、Oregon Health and Science University

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年12月1日

一次修了 (推定)

2028年9月1日

研究の完了 (推定)

2028年11月30日

試験登録日

最初に提出

2026年8月6日

QC基準を満たした最初の提出物

2026年11月11日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月11日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • STUDY00028866
  • 103326 (その他の助成金/資金番号:Merck Sharp & Dohme, LLC)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

De-identified data may be shared with qualified investigators upon request. Requests for access should include a brief description of the proposed research objectives, anticipated use of the data, and plans for data security and confidentiality. Data sharing will be considered for researchers with a legitimate scientific purpose, provided the proposed use is consistent with participant consent, applicable regulatory requirements, and institutional policies.

IPD 共有時間枠

IPD and supporting information will be available from the date of results publication to ten years post-publication.

IPD 共有アクセス基準

All requests will be reviewed by the Principal Investigator, who will evaluate whether: (1) the proposed use is appropriate and scientifically justified; (2) the requested data are necessary for the stated purpose; (3) the proposed use is consistent with participant consent and IRB requirements; and (4) adequate measures are in place to protect data confidentiality and security. Approved recipients may be required to execute a data use agreement prior to receiving study data.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • ICF

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する